Literature DB >> 20113690

Outcomes of transvaginal uterosacral ligament suspension: systematic review and metaanalysis.

Rebecca U Margulies1, Mary A M Rogers, Daniel M Morgan.   

Abstract

This systematic review of uterosacral ligament suspension provides a metaanalysis of anatomic outcomes and a summary of subjective outcomes. A successful anatomic outcome was considered present when women had "optimal" or "satisfactory" (pelvic organ prolapse quantification system stage 0 or 1) outcomes. In the anterior, apical, and posterior compartments, the pooled rates for a successful outcome were 81.2% (95% confidence interval [CI], 67.5-94.5%), 98.3% (95% CI, 95.7-100%), and 87.4% (95% CI, 67.5-94.5%). In the anterior compartment, women with preoperative stage 2 prolapse were more likely than those with preoperative stage 3 prolapse to have a successful anatomic outcome (92.4% vs 66.8%; P = .06). Outcomes, with respect to subjective symptoms, were reassuring; however, it was not possible to pool data because of methodologic differences between studies. Copyright 2010 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20113690     DOI: 10.1016/j.ajog.2009.07.052

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  45 in total

1.  Advanced uterovaginal prolapse: is vaginal hysterectomy with McCall culdoplasty as effective as in lesser degrees of prolapse?

Authors:  Alexandriah Alas; Neeraja Chandrasekaran; Hemikaa Devakumar; Laura Martin; Eric Hurtado; G Willy Davila
Journal:  Int Urogynecol J       Date:  2017-08-04       Impact factor: 2.894

2.  Traditional McCall culdoplasty compared to a modified McCall technique with double ligament suspension: anatomical and clinical outcomes.

Authors:  Silvia Parisi; Antonia Novelli; Elena Olearo; Alessandro Basile; Andrea Puppo
Journal:  Int Urogynecol J       Date:  2020-06-27       Impact factor: 2.894

3.  Surgical management of apical pelvic support defects: the impact of robotic technology.

Authors:  Ashley W Carroll; Elizabeth Lamb; Audra Jo Hill; Edward J Gill; Catherine A Matthews
Journal:  Int Urogynecol J       Date:  2012-04-12       Impact factor: 2.894

Review 4.  Traditional native tissue versus mesh-augmented pelvic organ prolapse repairs: providing an accurate interpretation of current literature.

Authors:  E J Stanford; A Cassidenti; M D Moen
Journal:  Int Urogynecol J       Date:  2011-11-09       Impact factor: 2.894

5.  Lajjalu treatment of uterine prolapse.

Authors:  T M Shivanandaiah; T M Indudhar
Journal:  J Ayurveda Integr Med       Date:  2010-04

6.  Uterosacral vault suspension (USLS) at the time of hysterectomy: laparoscopic versus vaginal approach.

Authors:  Sara Houlihan; Shunaha Kim-Fine; Colin Birch; Selphee Tang; Erin A Brennand
Journal:  Int Urogynecol J       Date:  2018-11-05       Impact factor: 2.894

7.  Diagnosis and Therapy of Female Pelvic Organ Prolapse. Guideline of the DGGG, SGGG and OEGGG (S2e-Level, AWMF Registry Number 015/006, April 2016).

Authors:  K Baeßler; T Aigmüller; S Albrich; C Anthuber; D Finas; T Fink; C Fünfgeld; B Gabriel; U Henscher; F H Hetzer; M Hübner; B Junginger; K Jundt; S Kropshofer; A Kuhn; L Logé; G Nauman; U Peschers; T Pfiffer; O Schwandner; A Strauss; R Tunn; V Viereck
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-12       Impact factor: 2.915

8.  Risk factors for ureteral occlusion during transvaginal uterosacral ligament suspension.

Authors:  Elisha Jackson; Jorge A Bilbao; Robert W Vera; Zuber D Mulla; Veronica T Mallett; T Ignacio Montoya
Journal:  Int Urogynecol J       Date:  2015-07-15       Impact factor: 2.894

9.  Uterosacral ligament vaginal vault suspension using delayed absorbable monofilament suture.

Authors:  Micheline J Wong; Azadeh Rezvan; Narender N Bhatia; Tajnoos Yazdany
Journal:  Int Urogynecol J       Date:  2011-06-17       Impact factor: 2.894

10.  Functional Outcomes for Incontinence and Prolapse Surgery.

Authors:  Saya Segal; Lily A Arya; Ariana L Smith
Journal:  Curr Bladder Dysfunct Rep       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.